Literature DB >> 350729

Antithrombin III: critical review of assay methods. Significance of variations in health and disease.

O R Odegård, U Abildgaard.   

Abstract

Thrombin or factor Xa added to plasma are inactivated by antithrombin III (At-III). The inactivation is accelerated by heparin, permitting assay systems which rapidly measure the At-III content of diluted plasma. Without heparin, the slow inactivation rates may be measured. Existing activity assays (fibrinogen or chromogenic substrates) and immunoassays of At-III have been reviewed. Correlation studies show a close correlation between the results of immunoassay and the results of most activity assays. In health, a narrow range of At-III has been found. The level is low in infancy. Fertile women have on the average somewhat lower levels than men. In old age, the level tends to drop. In clinical material studied with amidolytic assays, subnormal At-III levels were found in hereditary deficiency, liver disease, disseminated intravascular coagulation and in some cases with acute thrombosis. The amidolytic assays are rapid to perform, do not require experience in clotting technique and seem preferable in clinical routine work.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 350729     DOI: 10.1159/000214249

Source DB:  PubMed          Journal:  Haemostasis        ISSN: 0301-0147


  9 in total

Review 1.  Diagnosis and management of inherited and acquired thrombophilias.

Authors:  F A Spencer; R C Becker
Journal:  J Thromb Thrombolysis       Date:  1999-04       Impact factor: 2.300

Review 2.  Guidelines on the investigation and management of thrombophilia. The British Committee for Standards in Haematology.

Authors: 
Journal:  J Clin Pathol       Date:  1990-09       Impact factor: 3.411

Review 3.  The impact of inherited thrombophilia on surgery: a factor to consider before transplantation?

Authors:  Elias Kfoury; Ali Taher; Said Saghieh; Zaher K Otrock; Rami Mahfouz
Journal:  Mol Biol Rep       Date:  2008-05-31       Impact factor: 2.316

4.  Familial antithrombin III deficiency and Mycoplasma pneumoniae pneumonia.

Authors:  M D Creagh; I F Roberts; D J Clark; F E Preston
Journal:  J Clin Pathol       Date:  1991-10       Impact factor: 3.411

5.  Electrode adsorption method for determination of enzymatic activity.

Authors:  H Arwin; I Lundström; A Palmqvist
Journal:  Med Biol Eng Comput       Date:  1982-05       Impact factor: 2.602

6.  Coagulation studies on umbilical arterial and venous blood from normal newborn babies.

Authors:  H Jürgens; U Göbel; J Bokelmann; H von Voss; V Wahn
Journal:  Eur J Pediatr       Date:  1979-06-28       Impact factor: 3.183

7.  Antithrombin III Utilization in a Large Teaching Hospital.

Authors:  Cristina M Salas; Marta A Miyares
Journal:  P T       Date:  2013-12

8.  Comparison of three methods for the estimation of plasma antithrombin.

Authors:  D S McLellan; J D Devlin; G H Heyse-Moore; A Aronstam
Journal:  J Clin Pathol       Date:  1980-05       Impact factor: 3.411

9.  Patient-Specific Modelling of Blood Coagulation.

Authors:  N Ratto; A Bouchnita; P Chelle; M Marion; M Panteleev; D Nechipurenko; B Tardy-Poncet; V Volpert
Journal:  Bull Math Biol       Date:  2021-03-27       Impact factor: 1.758

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.